Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 12/20 | 0.50 |
| ▸ | HTR7 | P34969 | 12/20 | 0.50 |
| ▸ | HTR1D | P28221 | 3/20 | 0.49 |
| ▸ | HTR1B | P28222 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540873 | 1.00 | CHRM3 (0.67) | CHRM3CHRM2CHRM1DRD2DRD4 | |
| SCHEMBL9759621 | 0.84 | DRD2 (0.49) | CHRM3CHRM2CHRM1DRD2DRD4 | |
| SCHEMBL9759874 | 0.83 | DRD2 (0.58) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL14591348 | 0.82 | CHRM3 (0.47) | CHRM3CHRM2CHRM1 | |
| SCHEMBL14591308 | 0.81 | CHRM3 (0.69) | CHRM3CHRM2CHRM1DRD2DRD4 | |
| SCHEMBL8630151 | 0.80 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7HTR1D | |
| SCHEMBL7763389 | 0.80 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7HTR1D | |
| SCHEMBL8634782 | 0.80 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7HTR1D | |
| SCHEMBL8891132 | 0.80 | CHRM3 (1.00) | CHRM3CHRM2CHRM1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL6542162 | 0.80 | CHRM3 (0.67) | CHRM3CHRM2CHRM1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1051990-C | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes and 3-aminochromones | LILLY CO ELI (US) | 2000-05-03 | — | — | CN | disclosed |
| US-5637624-A | ANTISEROTONIN AGENT | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5594034-A | ADMINISTERING DIRECT ACTING 5-HYDROXYTRYPTAMINE AGONIST TO MAMMAL | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5594025-A | Method of inhibiting gastric acid secretion with 5-substituted-3-aminochromane | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | disclosed |
| US-5576352-A | Method of inhibiting gastric acid secretion with aryloxypropanolamines | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0451008-A1 | 8-Sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0447727-A1 | Novel 8-sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| US-5047422-A | Treating A Disorder Of The Central Nervous System, Cardiovascular System Or Intestinal Tract | BAYER AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| US-4968679-A | DISORDERS OF CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM OR INTESTINAL TRACT | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0385658-A1 | Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes | ELI LILLY AND COMPANY (US) | 1990-09-05 | — | — | EP | disclosed |
| CN-1045099-A | Ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes | LILLY CO ELI (US) | 1990-09-05 | — | — | CN | disclosed |
| US-4873262-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, CARDIIOVASCULAR SYSTEM OR INTESTINAL TRACT | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | disclosed |
| CN-87101285-A | 8-replaces-2-amino-1,2,3, the 4-tetrahydro-bitter edible plant | — | 1988-08-17 | — | — | CN | disclosed |
| EP-0272534-A2 | 8-substituted 2-aminotetralins | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | CHRM3 270/4885CHRM2 520/4885CHRM1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.